Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 6/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | CA4 | P22748 | 1/20 | 0.71 |
| ▸ | CA6 | P23280 | 1/20 | 0.71 |
| ▸ | CA7 | P43166 | 1/20 | 0.71 |
| ▸ | TPMT | P51580 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20873295 | 0.98 | TTR (0.97) | TTRCA12CA1CA2CA4 | |
| SCHEMBL7148225 | 0.93 | TTR (0.88) | TTRCA12CA1CA2CA4 | |
| SCHEMBL30601072 | 0.93 | TTR (0.88) | TTRCA12CA1CA2CA4 | |
| SCHEMBL26936560 | 0.90 | TTR (0.82) | TTRCA12CA1CA2CA4 | |
| SCHEMBL11462504 | 0.90 | TTR (0.81) | TTRCA12CA1CA2CA4 | |
| SCHEMBL29775216 | 0.89 | TTR (0.79) | TTRCA12CA1CA2CA4 | |
| SCHEMBL20759528 | 0.89 | TTR (0.79) | TTRCA12CA1CA2CA4 | |
| SCHEMBL20873293 | 0.87 | TTR (0.77) | TTRCA12CA1CA2CA4 | |
| SCHEMBL9315876 | 0.87 | TTR (0.77) | TTRCA12CA1CA2CA4 | |
| SCHEMBL30546226 | 0.87 | TTR (0.77) | TTRCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289811-A1 | DIARYL ETHER COMPOUND AND MANUFACTURING METHOD FROM LIGNIN | École Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
| EP-3463480-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | Sanofi (FR) | 2019-04-10 | — | — | EP | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100190832-A1 | Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates | NATIONAL INSTITUTE OF IMMUNOLOGY. | 2010-07-29 | — | — | US | disclosed |
| US-20100190832-A1 | Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates | NATIONAL INSTITUTE OF IMMUNOLOGY. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | GPR119, SLC2A8, SLC2A4 | TTR 1676/4885CA12 502/4885CA1 1797/4885 |
| US-20100190832-A1 | Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates | TTR, TPR, POT1 | TTR 1/4885CA12 4714/4885CA1 4369/4885 |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | TTR 1676/4885CA12 502/4885CA1 1797/4885 |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | NR3C1, NR3C2, MC2R | TTR 3753/4885CA12 4577/4885CA1 4563/4885 |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | TTR 1676/4885CA12 502/4885CA1 1797/4885 |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | TTR 1676/4885CA12 502/4885CA1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.